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adverse events were observed in 39% of pts; most frequently 
nausea (6%), diarrhea, dizziness, and rash (4% each). 
Dyspnea, syncope, raised GGT and sepsis (each 5%) were the 
most common grade ≥3  AEs. Among 29 evaluable HNSCC pts 
for efficacy, 4 pts had a partial response. Numerous anti-PD-
1/PD-L1 agents are currently tested in HNSCC. First 
randomized trial with nivolumab vs standard of care in 
second line after platinum based first line therapy has just 
closed. Randomized trials testing pembrolizumab and 
durvalumab in first-line or second-line treatment for R/M 
HNSCC patients are ongoing. Beside evaluation of efficacy, 
these studies should help define the best population (HPV 
status, prior therapies) and more useful biomarkers than 
threshold of PD-L1 expression, to select patients who can 
benefit from these new agents. Flare-up reaction with 
increase of tumor volume and immune-related adverse 
events may occur: new guidelines are needed to define 
criteria of response, time to stop treatment and management 
of toxicities. Some patients may have a fast progression 
under monotherapy and mechanisms of resistance are 
unclear. New approaches combining anti-PD-L1/PD-1 agents 
and other immune-modulators, chemotherapy and 
radiotherapy are currently explored. Abscopal effect related 
to anti-PD-L1/PD-1 agents seems promising. For locally 
advanced HNSCC, trials testing combinations with anti-PD-
L1/PD-1 agents in induction regimen and concurrent CRT are 
ongoing. The story of immunotherapy as a new paradigm in 
HNSCC is just beginning… 
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Stereotactic radiation of small brain targets provides high 
spatial resolution and accuracy for positioning of patient and 
radiation fields, almost on submillimeter ranges. This is not 
matched by equally sharp dose gradients, since finite source 
size, collimator design limitations and transport of electrons 
in the irradiated tissue all diffuses the dose. Not surprisingly, 
the dose prescriptions evolving for small brain tumors aimed 
for a specified dose to the target periphery, accepting 
whatever resulting dose to the target center. A kind of 
standard evolved aiming for a ratio of approximately 65% 
relative dose at the periphery versus the maximum target 
center dose (or 154% center-to-periphery ratio). This dose 
heterogeneity was considered favorable, as to more 
effectively treat presumably hypoxic cells at the tumor 
center. The stereotactic treatment methodology for brain 
treatments were in the early 1990s transferred to radiation 
of liver metastasis. Through use of stereotactic body frame 
high target positioning reproducibility was achieved, and 
similar dose prescriptions of heterogeneous dose were 
applied, with a center-to-periphery dose ratio of 
approximately 154%. Soon the technique was also applied to 
peripheral lung tumors.  
Following the development of 3D treatment planning systems 
in the late 1980s, ICRU responded to the need for consistent 
handling of geometrical uncertainties and launched in 1993 
the ICRU 50 report recommending the use of GTV, CTV and 
PTV to capture the uncertainties. Specifically, the role of 
PTV was to “ensure that the prescribed dose is actually 
absorbed in the CTV”. The normal use of the PTV is to plan a 
homogenous dose to its interior, through which it is assumed 
that the CTV gets the same dose as it is located in the PTV. 
This requires the dose inside the PTV to be both 
homogeneous and robust with respect to movements 
involving heterogeneities. The PTV concept was applied also 
for extracranial stereotactic body treatments, often 
inheriting a high center-to-periphery prescription. Dose 
calculations at the time used “class a” algorithms that not 
account for dose variations due to a varying level of lateral 
charged particle equilibrium caused by low density regions. 
Most so called pencil beam algorithms belong to this, class a, 
category. Accurate dose calculations can now be achieved 
with “class b” algorithms such as Monte Carlo, Collapsed 
Cone or Grid based Boltzmann equation solvers. However, for 
any algorithm that would calculate the dose physically 
correct, the resulting dose for the PTV is not representative 
for the CTV when the margin around the latter contains a 
lower density medium. Hence, the straight forward 
application of PTV based treated planning together with 
heterogeneous prescriptions principles (originally inherited 
from intracranial treatments), has created a confused 
situation with large uncertainties with respect to the actually 
delivered doses.  
A robust dosimetry can be achieved by realizing that the dose 
to a CTV surrounded by a low density medium will be 
independent of movements as long as it is exposed to a 
uniform fluence. Given that a near homogeneous fluence 
cover the PTV, dose prescriptions can then be done directly 
to the CTV based on a dose calculation with a “class b” 
algorithm (MC, CC or equivalent). As long as the movements 
of the CTV are kept well inside a PTV with a homogeneous 
fluence, the dose delivered to the CTV will be much closer to 
the prescribed dose, thus providing robust dose specification 
for small tumors. However, tools for optimization of uniform 
fluence are presently not provided in clinical TPS. Luckily, 
several workarounds exists that can “cheat” the optimization 
of homogenous dose to instead yield a effectively 
homogeneous fluence. From a pure physics point of view, this 
can be achieved by incapacitating the lateral spread of 
energy from the rays of the primary beam. In class a 
algorithms of the pencil beam kind, this can be implemented 
by changing the pencil beam parameter controlling the 
lateral spread. In point kernel algorithms such as CC, similar 
manipulation of kernel data can be done. In essence, in most 
algorithms fluence is a precursor for dose providing 
opportunities to access it. Alternatively, the density of the 
PTV can be set to a high value that shortens the electron 
transport distance enough to make the dose more fluence 
like.  
In summary, a robust small lung tumor dose can be 
implemented through a planning process in which the PTV is 
determined by the common practice addition of a setup 
margin to a MIP projections ITV, but replacing the common 
practice dose calculations by a fluence optimization followed 
by a class b dose calculation with the CC (or similar) 
algorithm, using absolute dose prescriptions to the CTV 
rather than the PTV. For a test series of 5 patients this 
procedure reduced the difference between prescribed and 
delivered dose to the CTV from 30% to 8% in D98, with a 
similar reduction for D02. 
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The current practice of cranial and extra-cranial stereotactic 
radiotherapy is in many ways influenced by Gamma-Knife 
Radiosurgery (GN-RS). It has been a key component of GN-RS 
to treat the target volumes without any safety margins (GTV 
= PTV) and to use inhomogeneous dose profiles within the 
target volume. The dose was most frequently prescribed to a 
low isodose e.g. 50% meaning that substantially higher doses 
are delivered to the central part of the tumor.  
This practice of dose prescription to a low target 
encompassing isodose line has been adopted in extra-cranial 
stereotactic radiotherapy (Stereotactic Body Radiotherapy 
